You are here

AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41AG044890-01A1
Agency Tracking Number: R41AG044890
Amount: $270,008.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIA
Solicitation Number: PA14-072
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
45 North Chatham Parkway
CHAPEL HILL, NC 27517-6040
United States
DUNS: 604014345
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (919) 966-0905
Business Contact
Phone: (919) 968-2727
Research Institution
STRATFORD, NJ 08084-1350
United States

 () -
 Nonprofit college or university

Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could provide a modest delay in progression would provide a significant reduction in the high level care required later in the disease. ThisPhase I proposal describes an Adeno-associated viral vector-based metabolic intervention strategy to combat age-related cognitive decline in the 5xFAD model of familial Alzheimer's disease. A broad range of neurodegenerative disorders manifest abnormalities in the metabolism of the abundant amino acid derivative N-acetyl-L-aspartic acid (NAA). Fluctuations in NAA concentration within the brain are generally accepted as an index of oxidative metabolic integrity in neurons. NAA synthesis and catabolism are p

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government